Core Insights - Treace Medical Concepts, Inc. reported financial results for Q4 and full-year 2025, highlighting a shift in product sales and expectations for future growth [1][3][4]. Financial Performance - Q4 2025 revenue was $62.5 million, a 9% decrease from $68.7 million in Q4 2024, primarily due to a shift towards lower-priced bunion kits [4]. - Gross profit for Q4 2025 was $50.4 million, with a gross margin of 80.6%, slightly down from 80.7% in Q4 2024 [4]. - Total operating expenses in Q4 2025 were $56.3 million, up 1% from $55.7 million in Q4 2024 [5]. - The net loss for Q4 2025 was $(9.4) million, or $(0.15) per share, compared to a net loss of $(0.5) million, or $(0.01) per share, in Q4 2024 [5]. - Adjusted EBITDA for Q4 2025 was $6.2 million, down from $11.1 million in Q4 2024 [5]. Full-Year Results - Full-year 2025 revenue was $212.7 million, a 2% increase from $209.4 million in 2024 [6]. - Gross profit for the full year was $169.8 million, with a gross margin of 79.8%, down from 80.4% in 2024 [6]. - Total operating expenses for 2025 were $223.9 million, slightly down from $224.0 million in 2024 [6]. - The full-year net loss was $(59.0) million, or $(0.93) per share, compared to $(55.7) million, or $(0.90) per share, in 2024 [7]. - Adjusted EBITDA loss for 2025 was $(3.9) million, significantly improved from $(11.0) million in 2024 [7]. Operational Highlights - The company increased its active surgeon base by 202, ending 2025 with 3,337 active surgeons, a 6% increase year-over-year [8]. - The company broadened its global patent portfolio to 135 granted patents and 199 pending applications [8]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities totaled $48.4 million as of December 31, 2025 [9]. - The company reduced cash usage by 46% to $27.3 million in 2025 compared to $50.5 million in 2024 [8][9]. 2026 Financial Outlook - The company projects full-year 2026 revenue guidance of $200 million to $212 million, indicating a decline of 6% to 0% compared to 2025 [10]. - Expected Adjusted EBITDA loss for 2026 is projected to be between $(4.0) million and $(6.0) million [10]. - Anticipated reduction in cash usage for 2026 is approximately 50% compared to 2025 [10].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in children aged two to 11 years who have moderate-to-severe symptoms despite treatment with antihistamines [1][2]. Group 1: Product Approval and Clinical Studies - Dupixent's positive opinion is based on data from the LIBERTY-CUPID clinical study program, which includes two phase 3 studies and a single-arm phase 3 study involving children aged two to 11 years [2]. - In the US, a supplemental biologics license application for Dupixent in children aged two to 11 years with CSU has been accepted for review, with a decision expected by April 2026 [3]. Group 2: Disease Background and Treatment Options - Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disease characterized by debilitating hives and recurring itch, often inadequately controlled by standard antihistamine treatments [5]. - Many patients with CSU experience uncontrolled symptoms despite treatment, leading to a significant impact on their quality of life [5]. Group 3: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL4) and interleukin-13 (IL13) signaling pathways, which are key drivers of type 2 inflammation [6]. - The drug has received regulatory approvals in over 60 countries for various indications, including CSU, and is currently being used to treat more than 1.4 million patients globally [7]. Group 4: Development and Future Prospects - Dupilumab is being jointly developed by Sanofi and Regeneron, with over 60 clinical studies involving more than 12,000 patients conducted to date [8]. - Sanofi and Regeneron are exploring additional indications for Dupixent, including chronic pruritus of unknown origin and lichen simplex chronicus, which are currently under clinical investigation [9].

HAGERSVILLE, Ontario, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex”) (TSX: BLX) and Six Nations of the Grand River Development Corporation (SNGRDC) announce the commercial commissioning of the Hagersville Battery Energy Storage Park, the largest operating battery energy storage facility in Canada. With a capacity of 300 MW / 1,200 MWh, the landmark project represents a significant milestone in Ontario’s energy transition and positions SNGRDC and Boralex as leaders in large-scale storage solution ...

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome ...

SHENZHEN, China, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced a strategic partnership with China Post Securities. By integrating Aurora Mobile’s intelligent push notification solution, JPush, the two companies have built a financial-grade messaging infrastructure to improve the speed, stability, and accuracy of digital financial services. As the securities industry ...

Total Q4 Revenue of $230.6 million, up 67% Year-over-Year; Service Revenue of $191.9 million, up 61% Year-over-Year Full Year Results at High End of 2025 Guidance Range for Revenue, Adjusted EBITDA and Free Cash Flow Gogo Galileo and 5G Expected to Ramp in 2026 Company Provides 2026 Financial Guidance BROOMFIELD, Colo., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Gogo Inc. (NASDAQ: GOGO) (“Gogo” or the “Company”), a leading global provider of broadband connectivity services for the business and military/government ...

FORT WORTH, Texas, Feb. 27, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that its Board of Directors declared a quarterly cash dividend on its common stock for the first quarter. A dividend of $0.10 per common share is payable on March 27, 2026 to stockholders of record at the close of business on March 13, 2026. This represents an 11% increase to Range’s quarterly cash dividend and provides an annualized dividend of $0.40 per share. RANGE RESOURCES CORPORATION (NYSE: RRC ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for M ...

Company Announcement - Brunswick Exploration Inc. has appointed Charles Kodors as Vice President – International Projects, recognizing his contributions to the company's international portfolio since its rebranding in 2020 [1][2] - Mr. Kodors has over 15 years of experience in the mining and exploration industry, previously serving as Exploration Manager for Osisko Metals and Senior Exploration Geologist for Kirkland Lake Gold [2] Stock Options and DSUs - The company granted 186,566 deferred share units (DSUs) to non-executive directors at a fair market value of $0.268 per DSU, which will vest one year from the grant date [3] - The Board of Directors approved the grant of incentive stock options to purchase up to 3,515,000 common shares at an exercise price of $0.235 per share, subject to a three-year vesting period and a five-year term [4] Company Overview - Brunswick Exploration is focused on grassroots exploration for lithium in Canada, Greenland, and Saudi Arabia, with a significant emphasis on the Mirage project, which has an Inferred Mineral Resource Estimate of 52.2 million tonnes grading 1.08% Li2O [5]

Core Viewpoint - Abaxx Technologies Inc. has launched trading for Enwex Netherlands, France, and Spain Onshore Wind futures, providing standardized tools to manage wind generation risk across major European renewable markets [1][2]. Group 1: Product Launch and Features - The newly introduced wind futures contracts are designed to hedge against the variability in electricity output caused by wind generation, which affects revenue and utilization for market participants [2]. - Each contract is euro-denominated, financially settled, and indexed to the respective Enwex Wind country index, which measures forecast wind conditions at 100 meters and expresses standardized generation utilization rates in €/MWh [3]. - Trading for these contracts is available from 1000 to 2400 SGT, Monday to Friday, excluding Singapore public holidays [4]. Group 2: Market Impact and Infrastructure - The introduction of wind futures across six major power markets establishes a consistent set of weather-indexed benchmarks, facilitating reference pricing for wind generation variability across different jurisdictions [4]. - Abaxx Exchange aims to support the transition to a low-carbon economy by providing market infrastructure that includes centrally-cleared, physically-deliverable futures contracts in various commodities [7]. Group 3: Company Overview - Abaxx Technologies focuses on creating smarter markets through improved tools, benchmarks, and technology to address significant societal challenges, including the energy transition [5]. - The company is the majority shareholder of Abaxx Singapore, which owns Abaxx Exchange and Abaxx Clearing, and operates Abaxx Spot, a platform for modernizing physical gold trading [6].